Erectile Dysfunction, Master Overview
The complete history, science, and clinical taxonomy of erectile dysfunction
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- N/A (overview entry; individual treatments vary)
Reference only. Not medical advice.
This is something to take to a clinician. The Atlas can tell you what is known about erectile dysfunction, master overview in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Erectile dysfunction is the consistent inability to attain or maintain an erection sufficient for satisfactory sexual performance. It is one of the oldest documented medical conditions, with treatments recorded in the Ebers Papyrus (~1550 BCE), the Huangdi Neijing (~200 BCE), and Sushruta's Samhita. Modern medicine recognizes ED as overwhelmingly vasculogenic and as a cardiovascular sentinel event that frequently precedes cardiac disease by years. This anchor entry maps the full lineage, epidemiology, mechanistic taxonomy, and diagnostic gold standards.
From the Ebers Papyrus to PDE5 inhibitors, the oldest documented men's health condition on earth.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
- Diagnostic taxonomy
- Vasculogenic (~70%, arterial insufficiency or venous leak); neurogenic (spinal cord injury, MS, diabetic neuropathy, post-prostatectomy); hormonal (hypogonadism, hyperprolactinemia, thyroid); psychogenic (performance anxiety, depression, relationship); drug-induced (beta blockers, SSRIs, antipsychotics, opioids); mixed (most clinical ED).
- Diagnostic gold standards
- Nocturnal penile tumescence and rigidity (NPTR) testing distinguishes organic from psychogenic; penile duplex ultrasound maps blood flow; morning testosterone/LH/FSH/prolactin panel for hormonal workup; fasting glucose, HbA1c, lipids for cardiovascular risk; the validated IIEF questionnaire as research standard.
How it works
Erection is a neurovascular event. Sexual stimulation triggers parasympathetic nitric oxide release in the penile endothelium and nerves; NO activates guanylate cyclase, raising cyclic GMP, which relaxes corpus cavernosum smooth muscle. Arterial inflow expands the corpora and compresses the emissary veins against the tunica albuginea, the veno-occlusive mechanism, trapping blood. ED arises when any link fails: arterial inflow (vasculogenic), nerve signaling (neurogenic), hormonal drive (endocrine), psychological arousal (psychogenic), or pharmacological interference.
The erectile apparatus comprises the paired corpora cavernosa (the primary erectile cylinders), the corpus spongiosum surrounding the urethra and forming the glans, the fibrous tunica albuginea sheath, Buck's fascia, and the neurovascular bundle. Penile arteries are 1-2mm in diameter, smaller than coronary arteries, which is why atherosclerotic narrowing manifests as ED before angina.
Why ED is a cardiovascular warning light
Because the cavernous arteries are narrower than the coronary arteries, the same systemic atherosclerosis that will eventually cause a heart attack restricts penile blood flow first. Vasculogenic ED therefore functions as an early sentinel of endothelial disease, typically preceding a cardiac event by 2-5 years. A man presenting with new vasculogenic ED warrants a full cardiovascular workup, the marketplace sells him a pill; good medicine investigates his arteries.
What people get wrong
Often saidED is a natural part of aging you just live with
ActuallyWhile prevalence rises with age, ED is frequently a treatable symptom of vascular, metabolic, or hormonal disease, and an early warning of cardiovascular risk that should be investigated, not ignored.
Often saidED is mostly in your head
ActuallyRoughly 70% of ED is vasculogenic. Purely psychogenic ED is the minority; most clinical ED is multifactorial and organic, which is why testing, not history alone, is required.
Often saidA pill fixes the underlying problem
ActuallyPDE5 inhibitors treat the symptom by enabling an erection in response to arousal. They do not reverse atherosclerosis, diabetes, or low testosterone driving the condition.
Who profits, and who pushes back
Irwin Goldstein
Erectile dysfunction is too often treated as a standalone plumbing problem rather than as a sentinel marker of systemic vascular disease, so the cardiovascular and metabolic workup it should prompt is frequently skipped.
Leonore Tiefer
Defining a normal range of sexual response as a disease entity drives over-diagnosis and pharmaceutical demand, sidelining relational, psychological, and contextual causes that pills cannot address.
Primary-care and screening reviewers
Routine hormonal and specialized vascular testing for uncomplicated ED has limited yield and can lead to over-investigation; a focused history and cardiovascular risk assessment usually suffice.
How we got here
One of the oldest documented treatments for erectile dysfunction appears in the Chinese Huangdi Neijing (Yellow Emperor's Classic of Internal Medicine, traditionally attributed to the legendary Yellow Emperor but compiled ~200 BCE), describing a 20-ingredient elixir for restoring male sexual function; the older Egyptian Ebers Papyrus (~1550 BCE) records remedies for what it called penis weakness. Ancient Chinese medicine framed ED as 'yang flabbiness' or 'yin flabbiness'; ginseng was documented by Emperor Shen Nung among the earliest remedies. In India, Sushruta's Samhita (~8th century BCE) gave the first documented description within Vajikarana, the Ayurvedic branch named for the vitality of a horse (vaji), encompassing diet, herbs, and sexual yoga. The Ebers Papyrus (~1550 BCE, Eighteenth Dynasty Egypt) described impotence as 'penis weakness,' distinguishing natural (age-related) from supernatural (spell-caused) types, with 37 plant-based treatments including ground crocodile heart and wood oil applied to the penis; a separate papyrus (~1700 BCE) recommended healing leaves and honey in a bandage. Greek and Roman physicians including Hippocrates documented organ consumption and Spanish fly (Lytta vesicatoria, the ground emerald beetle identified by Aristotle); Roman men wore talismans of cured goat and rooster genitalia, and Tiberius and Ovid recorded their own struggles. Medieval Europe attributed ED to demonic interference, the Malleus Maleficarum (1486) named witches as a cause, while Viking culture treated ED and small size as social failures. Persian medicine offered parallel pharmacopeias (Halim, bird's brain, sheep's head). By the late 19th century, physicians had begun to identify impaired penile blood flow as a primary mechanism of impotence. The pharmacological era began with Charles-Edouard Brown-Sequard (1889), who injected himself with dog and guinea pig testicle extracts and reported restored vitality (later dismissed as placebo but ancestral to testosterone science); Steinach and Voronoff transplanted testicular tissue in the 1920s for wealthy clients. The penile implant era opened in 1973 (Small-Carrion semi-rigid; Brantley Scott inflatable). Gilles Brindley demonstrated intracavernosal papaverine in 1983 by injecting himself on stage at a urology conference and dropping his trousers. Alprostadil was FDA-approved in 1995; sildenafil (Viagra), originally a cardiovascular candidate, was approved March 27, 1998, the inflection point that transformed the field.
- ~1550 BCEEbers Papyrus documents 'penis weakness' (Egypt)
- ~8th c. BCESushruta Samhita / Vajikarana (India)
- ~200 BCEHuangdi Neijing 20-ingredient elixir (China)
- 1486Malleus Maleficarum names witches as a cause
- Late 1800sPhysicians begin identifying impaired blood flow as a mechanism
- 1889Brown-Sequard testicle extract self-injection
- 1973Small-Carrion and Scott prostheses
- 1983Brindley demonstrates intracavernosal injection on stage
- 1995Alprostadil FDA-approved
- 1998Sildenafil (Viagra) FDA-approved
- 2003Tadalafil and vardenafil approved
- 2012Avanafil approved
Set against the alternatives
Treatment is tiered: first-line oral PDE5 inhibitors and lifestyle modification; second-line vacuum erection devices and intracavernosal/intraurethral therapy; third-line penile prosthesis for refractory cases. Lifestyle intervention has the strongest and least commercial evidence base; prosthesis has the highest patient satisfaction but is most invasive.
| Option | Line | Invasiveness | Note |
|---|---|---|---|
| Lifestyle / risk-factor control | Foundational | None | Treats vascular root cause |
| PDE5 inhibitors (oral) | First-line | Low | 70 percent or more respond |
| Vacuum erection device | First/second-line | Low | Drug-free, mechanical |
| Intraurethral alprostadil | Second-line | Moderate | Pellet, variable response |
| Intracavernosal injection | Second-line | Moderate | High efficacy, needle-based |
| Penile prosthesis | Last-line | Surgical | Definitive, irreversible |
What we do not know
- Can the cardiovascular sentinel window be operationalized into a validated screening protocol that improves cardiac outcomes?
- What is the true reversibility of vasculogenic ED with early aggressive risk-factor and endothelial intervention?
- How much of clinically labeled ED is primarily psychogenic versus organic in younger men, and is the apparent rise real or artefactual?
- Will regenerative approaches (stem cell, shockwave, gene therapy) ever restore native erectile tissue function rather than augment it?
- How should ED definitions and thresholds be standardized across epidemiological studies that currently disagree widely?
What could change
Low-intensity shockwave therapyAims to stimulate angiogenesis and restore vascular function rather than provide on-demand effect; evidence still maturingRegenerative and gene therapyStem-cell and gene-transfer approaches under early investigation to repair cavernosal nerve and endothelial damageMelanocortin and central-acting agentsTargeting central arousal pathways for ED unresponsive to peripheral vasodilatorsDigital risk stratificationUsing ED presentation as an entry point for automated cardiovascular and metabolic screening
At a glance
- US prevalence
- ~30 million men (NIH)
- Global 1995
- 152 million
- Global projected 2025
- 322 million
- Prevalence at 40
- ~40%
- Prevalence at 70
- ~70%
- Most common type
- Vasculogenic (~70%)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Erectile Dysfunction, Master Overview. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Massachusetts Male Aging Study (MMAS)1994
Established age-prevalence curve: ~40% at 40, ~70% at 70; identified obesity, smoking, diabetes, sedentary lifestyle as modifiable risks
NIH Consensus on Impotence1992
Reframed 'impotence' as 'erectile dysfunction' and emphasized organic vasculogenic causes
Global prevalence projection (Ayta et al.)1999
152 million men globally in 1995; projected 322 million by 2025